Lampropoulos Fred P.

Executive Chairman Lampropoulos sold 25,000 MMSI shares at $87.31; prior 4 same-ticker sells all well-timed (90d declines), current stock -21.0% from 52-week high.

Lampropoulos sold 25,000 shares (25.0K shares) of Merit Medical for $2,182,750.00, reducing holdings by 2.4% to 1,029,955 shares. His prior trade history at this ticker shows a consistent pattern: 4 of 4 prior sells at MMSI were well-timed at the 90-day mark, with returns of -11.1%, -3.9%, -1.7%, and -1.7% respectively, followed most recently by a June 2025 sale (-5.4% 90d return) and May 2025 sales (-5.3% and -1.7% 90d returns). The stock is currently trading -21.0% from its 52-week high of $110.29, suggesting the broader downtrend aligns with his historical selling pattern. While the cross-ticker track record shows 100.00% well-timed rate on 8 prior sells (avg 90d return -7.3%), the same-ticker history of repeated well-timed sales at MMSI specifically warrants attention to whether this sale reflects a known-pattern exit or a material change in conviction regarding the company's forward trajectory.

Executive Chairman Lampropoulos sells 20,000 shares of MMSI at $85.13; stock trades at $87.20 near 52-week mid-point, seller's 4 prior MMSI sales all negative 90-day performers.

Lampropoulos sold 20,000 shares (reducing holdings from 1,074,955 to 1,054,955) at $85.13, well below the current price of $87.20 and 20.9% below the 52-week high of $110.29. His prior trades at MMSI show a consistent pattern: all 4 prior measurable sales (on 2025-03-05, 2025-05-27, 2025-05-30, and 2025-06-05) yielded negative 90-day returns ranging from -5.3% to -9.1%, giving a 100% well-timed rate at this ticker. Across his broader open-market history across all tickers, he has executed 8 prior sells with an average 90-day return of -7.8% and a 90-day well-timed rate of 100%. The current sale follows this established pattern of selling before subsequent declines, though the stock's 30-day performance of +3.2% and near-midpoint valuation (between 52-week extremes) offer no immediate directional signal for this specific transaction.

CEO Lampropoulos sold 10,000 MMSI shares at $95.19; stock now $94.84. Pattern shows 5 of 5 recent MMSI sales all preceded declines.

Fred P. Lampropoulos, President and CEO, sold 10,000 shares at $95.19 on 2025-06-05, reducing holdings from 1,056,028 to 1,046,028 shares (a -0.9% reduction). The current price of $94.84 is -14.0% from the 52-week high of $110.29, and the stock has declined 1.0% over 30 days and 3.6% over 90 days. Most notably, this sale is part of an aggressive series of five consecutive sales at MMSI beginning in early March, with three measurable historical sales showing 30-day declines of -10.8% to -11.1% and 90-day declines of -8.8% to -9.1%; all three prior completed MMSI sales were well-timed, as the stock fell after each transaction. The current sale arrived just days after two prior sales on 2025-05-30 and 2025-05-27 (timing for which remains unmeasurable), suggesting sustained execution of a large position reduction at this ticker. Given the consistent adverse price movement following his prior MMSI sales, the pattern warrants observation of whether the current transaction—executed at $95.19, above the current $94.84—precedes further weakness.

MMSI CEO Fred P. Lampropoulos sold 10,000 shares at $95.12 on 2025-05-30 (total $951.2K); stock now at $94.60, -14.2% from 52-week high.

Lampropoulos sold 10,000 shares at $95.12, reducing his holdings from 1.07M to 1.06M shares (a -0.9% reduction). His cross-ticker track record shows a 100.00% well-timed rate on 5 prior sells with an average 90-day return of -8.9%, indicating a consistent pattern of selling before subsequent declines. At MMSI specifically, his 4 prior measurable sells (all on 2025-03-05) were uniformly well-timed at the 90-day mark, each posting -10.8% or -11.1% downside in the 30- and 90-day periods following the sale. The current stock price of $94.60 is -14.2% from the 52-week high of $110.29 and has declined -1.1% over 30 days and -9.8% over 90 days since the transaction date—a pattern consistent with his prior execution at this ticker. Fundamentally, MMSI shows solid metrics (net income of $30.1M on revenue of $355.4M, +7.9% annual growth), but the elevated P/E of 45.70 and the insider's demonstrated ability to exit before declines warrant attention to whether valuation or forward guidance factors are driving this liquidity event.

Merit Medical CEO LAMPROPOULOS FRED P sold 20,000 shares at $96.54 (May 27); stock now $94.82, -14.0% from 52-week high.

Merit Medical's President and CEO sold 20,000 shares at $96.54 on 2025-05-27, reducing his holdings by 1.8% to 1,066,028 shares. The transaction price sits between current market price ($94.82) and the 52-week high ($110.29), meaning the stock has declined 14.0% from its recent peak. LAMPROPOULOS FRED P's prior sells at MMSI, all executed on 2025-03-05, exhibited consistent 30-day declines averaging -10.8% to -11.1%, establishing a pattern of selling before or near downward pressure. His cross-ticker track record shows 4 prior open-market sells with an average 30-day return of -10.9%. The company carries a elevated P/E of 45.81 and quarterly net income of $30,147,000 on revenue of $355,351,000, with recent annual growth of 7.9%, presenting a growth stock profile. The timing and consistency of prior MMSI sales warrant monitoring of whether this latest transaction precedes further softening.

MMSI President/CEO Lampropoulos sold 34,319 shares for $3,564,069.23 on 2025-03-05, reducing stake 81.6%

Fred P. Lampropoulos, President and CEO of Merit Medical Systems, executed four separate sales totaling 34,319 shares for $3,564,069.23 on March 5, 2025, at a blended average price of $103.85. This disposition reduces his post-transaction holdings to 7,734 shares from a pre-transaction position of 42,054 shares—a net reduction of 81.6% of his prior holdings. The magnitude of this multi-transaction sale by the company's top executive warrants investor attention, particularly given the CEO's substantial prior stake and the concentrated nature of the disposition. Current market price sits at $101.73, reflecting a -5.8% decline over the past 30 days and -7.8% from the 52-week high of $110.29, positioning this sale near recent lows in the current trading range.